-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

616.O1.6 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Triplet Combinations of Novel Therapies

Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Acute Myeloid Malignancies, AML, Non-Biological therapies, Workforce, Diversity, Equity, Inclusion, and Accessibility (DEI/DEIA) , Diseases, Therapies, Myeloid Malignancies
Sunday, December 12, 2021: 9:30 AM-11:00 AM
B302-B303, Level 3, Building B (Georgia World Congress Center)
Moderators:
Johnnie J. Orozco, MD, PhD, Fred Hutchinson Cancer Research Center and Norbert Vey, MD, Institut Paoli Clamettes
Disclosures:
Orozco: Actinium Pharmaceuticals, Inc.: Other: site PI for clinical trial(s) sponsored by Actinium, Research Funding. Vey: Amgen: Honoraria; BMS: Honoraria; BIOKINESIS: Consultancy, Research Funding; NOVARTIS: Consultancy, Honoraria, Research Funding; SERVIER: Consultancy; JAZZ PHARMACEUTICALS: Honoraria; JANSSEN: Consultancy, Honoraria; Abbvie: Honoraria.
9:30 AM

Patrick K Reville, MD, MPH1, Hagop Kantarjian, MD2, Gautam Borthakur, MD2, Naveen Pemmaraju, MD2, Courtney D. DiNardo, MD, MSCE2, Koji Sasaki, MD3, Naval Daver, MD4, Ghayas C. Issa, MD2, Maro Ohanian, DO2*, Guillermo Montalban-Bravo, MD2, Nicholas Short, MD5, Nitin Jain, MD3, Kapil N. Bhalla, MD2, Elias Joseph Jabbour, MD6, Alessandra Ferrajoli, MD2, Koichi Takahashi, MD, PhD2, Caitlin R. Rausch, PharmD7*, Rashmi Malla, RN, BSN2*, Kelly Marek2*, Mark Brandt, BS2*, Uday R. Popat, MD8, Michael Andreeff, MD, PhD2, Guillermo Garcia-Manero, MD2, Marina Konopleva, MD, PhD2, Farhad Ravandi, MB Bs9 and Tapan M. Kadia, MD10

1Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
3Department of Leukemia, MD Anderson Cancer Center, Houston, TX
4MD Anderson Cancer Center, Houston, TX
5Department of Leukemia, The University of Texas MD Anderson Cancer Center, HOUSTON, TX
6Department of Leukemia, University of Texas M.D. Anderson Cancer Ctr., Houston, TX
7Department of Pharmacy, University of Texas MD Anderson Cancer Center, Houston, TX
8Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
9Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
10Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX

9:45 AM

Chong Chyn Chua, MBBS, FRACP, FRCPA1,2,3, John Reynolds, PhD2,4*, Anoop Kumar Enjeti, MBBS, FRCPA, FRACP, PhD, MD, MRCP2,5, Devendra Hiwase, MBBS, MD, FRACP, FRCPA, PhD2,6, Paula Marlton2,7, Ashish Bajel, MBBS, FRACP, FRCPA2,8,9, Shuh Ying Tan, MBBS2,10*, Edward S. Morris, BMBS, DM2,11, Chun-Kei-Kris Ma, BSc(Med), MBBS, PhD, FRACP, FRCPA2,12*, Carolyn Grove, MBBS, PhD2,13*, Julian Cooney, MBBS, FRACP, FRCPA2,14, Ashanka Beligaswatte, MBBS, FRACP, FRCPA2,15*, Natasha Anstee, PhD3,16*, Stephen B Ting, MBBS, FRACP, FRCPA, PhD2,17*, Travis Perera, MB ChB, FRACP, FRCPA2,18*, Amanda Johnston, MBBS, FRACP, FRCPA2,19, David Ritchie, MB ChB, PhD, FRACP, FRCPA2,9,20 and Andrew H. Wei, MBBS, PhD2,3,16

1The Alfred Hospital & Monash University, Melbourne, VIC, Australia
2Australasian Leukaemia and Lymphoma Group (ALLG), Melbourne, VIC, Australia
3Australian Centre for Blood Diseases, Monash University, Melbourne, VIC, Australia
4The Alfred and Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia
5Department of Haematology, Calvary Mater Newcastle Hospital, Sydney, NSW, Australia
6Department of Haematology, Royal Adelaide Hospital, Adelaide, SA, Australia
7Princess Alexandra Hospital and University of Queensland, Brisbane, Australia
8Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia
9Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia
10Department of Haematology, St Vincent’s Hospital, Melbourne, VIC, Australia
11Townsville Cancer Centre, Townsville, QLD, Australia
12Department of Haematology, Westmead Hospital, Sydney, NSW, Australia
13Department of Haematology, PathWest & Sir Charles Gairdner Hospital, Department of Health, Nedlands, WA, Australia
14Department of Haematology, Fiona Stanley Hospital, Perth, WA, Australia
15Department of Haematology, Flinders Medical Centre, Adelaide, Australia
16Department of Haematology, The Alfred Hospital, Melbourne, VIC, Australia
17Department of Haematology, Box Hill Hospital and Monash University Eastern Health Clinical School, Melbourne, VIC, Australia
18Wellington Blood and Cancer Centre, Wellington, New Zealand
19Westmead Hospital, Westmead, NSW, Australia
20Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC, Australia

10:00 AM

Gail J. Roboz, MD1, Thomas Pabst, MD2, Ahmed Aribi, MD3, Joseph M. Brandwein, MD4*, Hartmut Döhner, MD5, Walter Fiedler, MD6, Domenica Gandini, MD, PHD7*, Michelle Geddes, MD, FRCPC8*, Jing-Zhou Hou, MD, PhD9, Angela J. Howes, BSc, PhD10, Anna Hultberg, PhD7*, Eric Huselton, MD11, Julie Jacobs, PhD12*, Colleen Kane, PhD, VMD13, Ewa Lech-Marańda, MD, PhD14*, Marieke Louwers, PhD7*, Kerri Nottage, MD, MPH15*, Uwe Platzbecker, MD16, Raajit Rampal, MD, PhD17, Mariya Salman, PhD15*, Priya Shah, MBBS18*, Don Stevens, MD19, Monic Stuart, MD, MPH7*, Marion Subklewe, MD20, Anne Sumbul, MSc7*, Eunice S. Wang, MD21, Agnieszka Wierzbowska, MD, PhD22*, Bin Yao7*, Karen Yee, MD23, Hagop Kantarjian, MD24 and Gautam Borthakur, MD25

1Division of Hematology Oncology, Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY
2Department of Medical Oncology, University Hospital, Bern, Switzerland
3City of Hope National Medical Center, Duarte, CA
4University of Alberta, Edmonton, Canada
5Department of Internal Medicine III, Bone Marrow Transplantation Unit, University Hospital of Ulm, Ulm, Germany
6Universitätsklinik Hamburg-Eppendorf, Hamburg, Germany
7argenx, Ghent, Belgium
8Tom Baker Cancer Centre, Calgary, Canada
9University of Pittsburgh School of Medicine, Pittsburgh, PA
10Janssen R&D, High Wycombe, PA, United Kingdom
11University of Rochester, Rochester, NY
12argenx, Ghent, MA, Belgium
13Janssen R&D, Spring House, PA
14Instytut Hematologii i Transfuzjologii Indiry Gandhi 14, Warsaw, Poland
15Janssen R&D, Raritan, NJ
16Universitätsklinikum Leipzig, Leipzig, Germany
17Memorial Sloan Kettering Cancer Center, New York, NY
18Janssen R&D, High Wycombe, ENG, United Kingdom
19Norton Healthcare, Norton Cancer Institute, Louisville, KY
20Klinikum der Universität München, Munich, Germany
21Roswell Park Comprehensive Cancer Center, BUFFALO, NY
22Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im., Lodz, Poland
23Princess Margaret Cancer Centre, Toronto, ON, Canada
24University of Texas MD Anderson Cancer Center, Houston, TX
25MD Anderson Cancer Center, The University of Texas, Houston, TX

10:15 AM

Musa Yilmaz, MD1, Muharrem Muftuoglu, MD2, Hagop Kantarjian, MD3, Courtney D. DiNardo, MD, MSCE3, Tapan M. Kadia, MD3, Marina Konopleva, MD, PhD3, Gautam Borthakur, MD4, Naveen Pemmaraju, MD3, Nicholas Short, MD5, Yesid Alvarado, MD3, Abhishek Maiti, MBBS3*, Lucia Masarova, MD6*, Guillermo Montalban-Bravo, MD3, Carissa Jurisprudencia7*, Allison M. Pike, RN8*, Sanam Loghavi, MD9, Keyur Patel, MD, PhD10*, Guilin Tang, MD, PhD10*, Jairo A. Matthews4*, Steven Kornblau, MD4, Elias Joseph Jabbour, MD11, Guillermo Garcia-Manero, MD12, Vivian Ruvolo, MS2*, Farhad Ravandi, MB Bs3, Michael Andreeff, MD, PhD3 and Naval Daver, MD3

1Department of Leukemia, MD Anderson Cancer Center, Houston, TX
2Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
3Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
4Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
5Department of Leukemia, The University of Texas MD Anderson Cancer Center, HOUSTON, TX
6University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX
7MD Anderson Cancer Center, Houston, TX
8The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX
9Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX
10Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
11Department of Leukemia, University of Texas M.D. Anderson Cancer Ctr., Houston, TX
12The University of Texas MD Anderson Cancer Center, Houston, TX

10:30 AM

Naval Daver, MD1, Marina Konopleva, MD, PhD2, Abhishek Maiti, MBBS2*, Tapan M. Kadia, MD3, Courtney D. DiNardo, MD, MSCE2, Sanam Loghavi, MD4, Naveen Pemmaraju, MD2, Elias Joseph Jabbour, MD5, Guillermo Montalban-Bravo, MD2*, Guilin Tang, MD, PhD6*, Koji Sasaki, MD7, Gautam Borthakur, MD8, Musa Yilmaz, MD9, Joie Alvarez, BSN2*, Michelle Golez10*, Sherry A. Pierce, BSN, BA2*, Graciela M. Nogueras González, MPH11*, Jing Ning12*, Hussein A Abbas, MD, PhD13, Farhad Ravandi, MB Bs14, Guillermo Garcia-Manero, MD2 and Hagop Kantarjian, MD2

1MD Anderson Cancer Center, Houston, TX
2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
3Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX
4Department of Hematopathology, MD Anderson, Houston, TX
5Department of Leukemia, University of Texas M.D. Anderson Cancer Ctr., Houston, TX
6Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
7Department of Leukemia, MD Anderson Cancer Center, Houston, TX
8MD Anderson Cancer Center, The University of Texas, Houston, TX
9Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX
10The University of Texas MD Anderson Cancer Center, Houston, TX
11Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
12department of biostatics, The University of Texas, M.D. Anderson Cancer Center, Houston, TX
13Division of Cancer Medicine, Medical Oncology Fellowship, UT M. D. Anderson Cancer Center, Houston, TX
14Department of Leukemia, The University of Texas MD Anderson Cancer Center, HOUSTON, TX

10:45 AM

Naval Daver, MD1, Ahmed Aribi, MD2, Pau Montesinos, PhD, MD3*, Gail J. Roboz, MD4, Eunice S. Wang, MD5, Roland B. Walter, MD, PhD, MS6, Deepa Jeyakumar, MD7, Daniel J. DeAngelo, MD, PhD8*, Harry P. Erba9, Anjali Advani, MD10, Patrick W. Burke, MD11, Giovanni Martinelli, MD12, Lauris Gastaud, MD13*, Xavier Thomas, MD, PhD14, Jessica K. Altman, MD15, Lourdes M. Mendez, MD, PhD16, Adolfo de la Fuente, MD17*, Elisabetta Todisco, MD, PhD18*, Gianluca Gaidano, MD19, Antonio Curti, MD, PhD20, Nicolas Boissel, MD, PhD21, Christian Recher, MD22, Christoph Schliemann, Prof., MD23*, Marina Konopleva, MD, PhD1, David A. Sallman, MD24, Laura Torres, MD25*, Guido Marcucci, MD26, Hagop Kantarjian, MD27, Callum M Sloss, PhD28, Kara E Malcolm, RN28*, Patrick A Zweidler-McKay, MD, PhD28 and Kendra Sweet, MD24

1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA
3Hospital Universitari i Politècnic La Fe, Valencia, Spain
4Division of Hematology & Medical Oncology, Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY
5Roswell Park Comprehensive Cancer Center, Buffalo, NY
6Fred Hutchinson Cancer Research Center, Seattle, WA
7University of California Irvine, Chao Family Comprehensive Cancer Center, Orange, CA
8Department of Medical Oncology, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA
9Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC
10Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
11Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI
12Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology “L. e A. Seràgnoli”, Bologna, Italy
13Medical Oncology Department, Antoine Lacassagne Hospital, Nice, France
14Department of Hematology, Hospices Civils de Lyon, Lyon-Sud Hospital, Lyon, France
15Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL
16Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
17MD Anderson Cancer Center Madrid, Madrid, Spain
18Division of Onco-Hematology, European Institute of Oncology IRCCS, Milano, Italy
19Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy
20IRCCS Azienda ospedaliero-universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy
21Université de Paris, Service Hématologie, Hôspital Saint-Louis, Paris, France
22Service d'Hématologie, CHU de Toulouse - Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
23Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany
24Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
25Hematology Department, Hospital Universitario La Fe de Valencia, Valencia, Spain
26Department of Hematologic Malignancies Translational Science, Gehr Family Center for Leukemia Research, Hematologic Malignancies and Stem Cell Transplantation Institute, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA
27The University of Texas MD Anderson Cancer Center, Houston, TX
28ImmunoGen, Waltham, MA

*signifies non-member of ASH